Jefferies Upgrades Arbutus Biopharma (ABUS) to Buy
Tweet Send to a Friend
Jefferies analyst Dennis Ding upgraded Arbutus Biopharma (NASDAQ: ABUS) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


